Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

Jia-Tsrong Jan(Genomics Research Center, Academia Sinica), Ting-Jen Rachel Cheng(Genomics Research Center, Academia Sinica), Yu-Pu Juang(National Taiwan University), Hsiu‐Hua Ma(Genomics Research Center, Academia Sinica), Ying‐Ta Wu(Genomics Research Center, Academia Sinica), Wen‐Bin Yang(Genomics Research Center, Academia Sinica), Cheng‐Wei Cheng(Genomics Research Center, Academia Sinica), Xiaorui Chen(Genomics Research Center, Academia Sinica), Ting-Hung Chou(Institute of Chemistry, Academia Sinica), Jiun‐Jie Shie(Institute of Chemistry, Academia Sinica), Wei‐Chieh Cheng(Genomics Research Center, Academia Sinica), Rong‐Jie Chein(Institute of Chemistry, Academia Sinica), Shi‐Shan Mao(Genomics Research Center, Academia Sinica), Pi‐Hui Liang(National Taiwan University), Che Ma(Genomics Research Center, Academia Sinica), Shang‐Cheng Hung(Genomics Research Center, Academia Sinica), Chi‐Huey Wong(Scripps Research Institute)
Proceedings of the National Academy of Sciences
January 15, 2021
Cited by 190Open Access
Full Text

Abstract

Significance COVID-19 is a global pandemic currently lacking an effective cure. We used a cell-based infection assay to screen more than 3,000 agents used in humans and animals and identified 15 with antiinfective activity, ranging from 0.1 nM to 50 μM. We then used in vitro enzymatic assays combined with computer modeling to confirm the activity of those against the viral protease and RNA polymerase. In addition, several herbal medicines were found active in the cell-based infection assay. To further evaluate the efficacy of these promising compounds in animal models, we developed a challenge assay with hamsters and found that mefloquine, nelfinavir, and extracts of Ganoderma lucidum (RF3), Perilla frutescens , and Mentha haplocalyx were effective against SARS-CoV-2 infection.


Related Papers

No related papers found

Powered by citation graph analysis